Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Alicia Grande - VP, CFO, and Treasurer Patrick J. McEnany - Chairman, President, and CEO Jeff Del Carmen - Chief Commercial Officer Steven R.

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Call Transcript

Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates

Catalyst Pharmaceuticals topped fourth-quarter expectations and delivered strong guidance. In response, CPRX stock rose late Wednesday.

Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.

Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should Know

CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently published in Epilepsia showed that perampanel reduces seizures with high effectivity in patients with rare genetic epileptic disease. The article is available online at https://onlinelibrary.wiley.com/doi/10.1111/epi.17530.

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

Costco

These two stocks are entirely different, but they both make shareholders richer.

2 Breakout Growth Stocks to Buy for the Long Haul

The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

Lamb Weston Hlds

Northeast Community Bancorp

Lamb Weston (LW), Catalyst Pharmaceuticals (CPRX) and Northeast Community Bancorp (NECB) are some of the top picks with a high net income ratio.

3 Top Profitable Stocks to Buy on Solid Net Income Ratio

Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?

Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on It

Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes"

Spotlight On Raising Awareness for Rare Diseases on February 28, 2023

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know

Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric.

Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic?

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why

AGCO

Jabil

Patterson-UTI Energy

Urban Outfitters

Stocks with high earnings yield have the potential to provide greater returns. PTEN, JBL, CPRX, AGCO and URBN are some stocks boasting high earnings yield to power your portfolio.

5 Best High Earnings Yield Picks to Grow Your Wealth

2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

Axcelis Technologies

Darling Ingredients

ICON

Lattice Semiconductor

ServiceNow

Performance Food Group

The search for growth stocks, or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings back into their core business.

The 7 Best Growth Stocks to Buy for February 2023

Catalyst's rights acquisition of FYCOMPA is a significant step towards controlling the epilepsy treatment market share. The company's cash balance of $256 million is enough to fund its CapEx in 2023.

Catalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement Concerns

Catalyst Pharmaceuticals, Inc. has been hit with an ANDA notice from Teva Pharmaceutical Industries Limited. Firdapse, at the heart of the ANDA, has had problems before.

Catalyst Pharmaceuticals: The Firdapse Complexity Does Not End

Dycom Industries

World Wrestling Entertainment

World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence

iShares Nasdaq Biotechnology ETF

Inspire Medical Systems Inc

Novocure

Revance Therapeutics

Teva Pharmaceutical

Vertex Pharmaceuticals

Zai Lab Ltd.

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

News for Catalyst Pharmaceuticals Stock (CPRX)